Lucid Diagnostics Inc Raises 25.69M in Share Offering by Selling Stockholders
May 27, 2023
Trending News ☀️
Lucid Diagnostics ($NASDAQ:LUCD) Inc, a leading diagnostics company, has recently announced that they have raised 25.69M in share offering by selling stockholders. According to Investing.com, this is the first time that Lucid Diagnostics Inc has made such a large offering. Their cutting-edge technology has enabled diagnosis and treatment of a range of diseases that can be easily monitored from one platform.
The new share offering will be used to further expand and grow their business, helping to increase access to quality healthcare solutions. By taking advantage of the latest advances in technology, Lucid Diagnostics Inc is helping to revolutionize the field of diagnostics by providing customers with the best possible care.
Share Price
On Tuesday, LUCID DIAGNOSTICS Inc. announced that it had successfully raised 25.69M in an offering of shares held by existing stockholders. At the close of the market, LUCID DIAGNOSTICS’ stock price was 1.5, down 2.5% from the prior closing price of 1.6. The funds raised will be used to expand LUCID DIAGNOSTICS’ product lines and services, as well as to support research and development initiatives. Additionally, the additional capital will allow LUCID DIAGNOSTICS to remain competitive in the diagnostics marketplace and continue its mission of providing advanced diagnostics services. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Lucid Diagnostics. More…
| Total Revenues | Net Income | Net Margin |
| 0.63 | -60.15 | -9487.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Lucid Diagnostics. More…
| Operations | Investing | Financing |
| -30.95 | -3.98 | 26.53 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Lucid Diagnostics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 49.12 | 24.22 | 0.6 |
Key Ratios Snapshot
Some of the financial key ratios for Lucid Diagnostics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -9481.9% |
| FCF Margin | ROE | ROA |
| -5004.9% | -156.7% | -76.5% |
Analysis
At GoodWhale, we have conducted an analysis of LUCID DIAGNOSTICS‘s wellbeing. The Star Chart shows that LUCID DIAGNOSTICS is strong in growth, medium in asset and weak in dividend, profitability. We classify LUCID DIAGNOSTICS as ‘rhino’, a type of company we conclude that has achieved moderate revenue or earnings growth. Given this assessment, investors who are looking for a steady and moderately growing company could find LUCID DIAGNOSTICS attractive. Furthermore, the company has an intermediate health score of 4/10 with regard to its cashflows and debt, making it likely to safely ride out any crisis without the risk of bankruptcy. More…
Peers
Its competitors are Motus GI Holdings Inc, CVRx Inc, and Imagin Medical Inc. Lucid Diagnostics Inc has a wide range of products and services, and it is a leading provider of diagnostic and therapeutic devices.
– Motus GI Holdings Inc ($NASDAQ:MOTS)
Motus GI Holdings Inc is a publicly traded company with a market capitalization of $5.6 million as of early 2022. The company has a negative return on equity of 183.03%, meaning that it has lost money for shareholders over the past year. Motus GI Holdings is a medical device company that specializes in developing endoscopy products for the diagnosis and treatment of gastrointestinal disorders. The company’s flagship product is the Motus GI System, which is a minimally invasive endoscopic platform that allows physicians to perform procedures in a less invasive way.
– CVRx Inc ($NASDAQ:CVRX)
The company’s market cap is 255.66M and ROE is -20.86% as of 2022. The company is a provider of healthcare products and services.
– Imagin Medical Inc ($OTCPK:IMEXF)
Imagin Medical Inc is a medical device company that focuses on the development of minimally invasive optical imaging technologies for early cancer detection. The company’s market cap is 1.31M as of 2022 and its ROE is 33.13%. Imagin’s main product is the i/Blue Imaging System, which is a handheld, battery-operated device that uses blue light to visualize potential cancerous and precancerous cells in real-time during surgery. The company is headquartered in Vancouver, Canada.
Summary
Lucid Diagnostics Inc. has announced a 25.69 million share offering by selling stockholders. This offering provides investors with an opportunity to gain exposure to the company, as the proceeds from the offering will be used to fund further research and development of the company’s products and services. One of the most attractive aspects of investing in Lucid Diagnostics is its innovative technology and strong intellectual property portfolio. The company has developed a number of health diagnostics and biotechnology-related products, and has been issued multiple patents for its proprietary technology.
Additionally, the company’s products have been approved by the FDA, demonstrating its commitment to safety and quality. Lucid Diagnostics has a strong team of executives and advisors, and is well positioned to capitalize on the growth potential of its products. All in all, Lucid Diagnostics offers investors an opportunity to invest in a dynamic, promising company.
Related Posts
Recent Posts
